ImmuCell Salute del bilancio

Salute finanziaria criteri di controllo 5/6

ImmuCell ha un patrimonio netto totale di $26.4M e un debito totale di $10.9M, che porta il suo rapporto debito/patrimonio netto a 41.3%. Le sue attività totali e le sue passività totali sono rispettivamente $44.4M e $18.0M.

Informazioni chiave

41.3%

Rapporto debito/patrimonio netto

US$10.90m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$3.81m
Patrimonio netto	US$26.41m
Totale passività	US$18.04m
Totale attività	US$44.45m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $13.9M ) di IUL superano le sue passività a breve termine ( $4.5M ).

Passività a lungo termine: Le attività a breve termine di IUL ( $13.9M ) superano le sue passività a lungo termine ( $13.6M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 26.9% ) di IUL è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di IUL è aumentato da 29.9% a 41.3% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: IUL ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: IUL ha una liquidità sufficiente per 1.1 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 14.4 % ogni anno.

ImmuCell Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

ImmuCell Corporation announced delayed 10-Q filing

Recent updates

Third quarter 2024 earnings released: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023)

ImmuCell Corporation to Report Q3, 2024 Results on Nov 13, 2024

Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023)

ImmuCell Corporation to Report Q2, 2024 Results on Aug 13, 2024

New minor risk - Share price stability

ImmuCell Corporation Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

First quarter 2024 earnings released: US$0.056 loss per share (vs US$0.30 loss in 1Q 2023)

ImmuCell Corporation to Report Q1, 2024 Results on May 14, 2024

ImmuCell Corporation, Annual General Meeting, Jun 13, 2024

ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million.

ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million.

Full year 2023 earnings released: US$0.74 loss per share (vs US$0.32 loss in FY 2022)

ImmuCell Corporation to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.085 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.088 loss in 2Q 2022)

ImmuCell Corporation to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

ImmuCell Corporation Appoints Bryan K. Gathagan to Board of Directors

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.095 profit in 1Q 2022)

ImmuCell Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$322 loss per share (vs US$10.31 loss in FY 2021)

Full year 2022 earnings released: US$0.32 loss per share (vs US$0.01 loss in FY 2021)

ImmuCell Corporation to Report Fiscal Year 2022 Results on Feb 21, 2023

Insufficient new directors

David S. Cunningham Intends to Retire from the Board of Directors of David S. Cunningham

ImmuCell Corporation, Annual General Meeting, Jun 15, 2023

ImmuCell Corporation announced delayed 10-Q filing

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.018 profit in 2Q 2021)

ImmuCell Corporation to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: EPS: US$0.095 (vs US$0.061 loss in 1Q 2021)

ImmuCell Corporation to Report Q1, 2022 Results on May 12, 2022

Mark Wustenberg, DVM Joins Sales and Marketing Team as Commercial Leader of Stakeholder Engagement of ImmuCell Corporation

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: US$0.01 loss per share (vs US$0.14 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmuCell Corporation to Report Q4, 2021 Results on Feb 22, 2022

Third quarter 2021 earnings released: EPS US$0.019 (vs US$0.045 loss in 3Q 2020)

Immucell Corporation Announces FDA Has Issued Technical Section Incomplete Letter Covering the Chemistry

Second quarter 2021 earnings released: EPS US$0.018 (vs US$0.11 loss in 2Q 2020)

Independent Director Jonathan Rothschild has left the company

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.017 loss in 1Q 2020)

Insider recently bought €1.3m worth of stock

Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019)

Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019)

Revenue beats expectations

ImmuCell Corporation to Report Fiscal Year 2020 Results on Feb 22, 2021

New 90-day high: €9.35

New 90-day high: €5.75

New 90-day high: €5.20

Third quarter 2020 earnings released: US$0.045 loss per share

ImmuCell Corporation to Report Q3, 2020 Results on Nov 12, 2020

ImmuCell Corporation to Report Q2, 2020 Results on Aug 12, 2020

ImmuCell Corporation(NasdaqCM:ICCC) dropped from Russell Microcap Growth Index

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane